Evaro, a UK-based healthcare infrastructure company, has raised $25M in Series A funding led by AlbionVC. The round included participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI.
The Norfolk-based company provides regulated healthcare infrastructure—including asynchronous consultations, prescribing, dispensing, and aftercare—that brands can embed into their platforms. Current partners include period tracking app Clue and sexual wellness retailer Lovehoney.
Evaro reports it has served over 2 million patients and holds CQC, GPhC, and NHS licenses. The company says brand integrations can be completed in as little as two weeks.
“When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity,” said Dr. Thuria Wenbar, CEO and co-founder of Evaro. “What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing. We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”
“Patients now expect the same convenience from healthcare that they get from banking or shopping—instant, mobile, on their terms,” said Dr. Oskar Wenbar, Chief Medical Officer and co-founder. “The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits – with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026.”
The funding will support expansion across treatment areas including women’s health, men’s health, and longevity medicine. Evaro was founded in 2018 by emergency physician Dr. Thuria Wenbar and pharmacist researcher Dr. Oskar Wenbar.
